Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $604.82 million. The enterprise value is $380.32 million.

Market Cap	604.82M
Enterprise Value	380.32M

Important Dates

The last earnings date was Tuesday, May 6, 2025, after market close.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Bionics has 43.36 million shares outstanding. The number of shares has increased by 150.89% in one year.

Current Share Class	43.36M
Shares Outstanding	43.36M
Shares Change (YoY)	+150.89%
Shares Change (QoQ)	+360.80%
Owned by Insiders (%)	3.13%
Owned by Institutions (%)	18.08%
Float	31.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.50
Forward PS	7.07
PB Ratio	1.93
P/TBV Ratio	1.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.88, with a Debt / Equity ratio of 0.02.

Current Ratio	15.88
Quick Ratio	14.58
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-16.93%
Revenue Per Employee	$237,517
Profits Per Employee	-$241,371
Employee Count	294
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	13.20
200-Day Moving Average	n/a
Relative Strength Index (RSI)	59.38
Average Volume (20 Days)	418,164

Short Selling Information

The latest short interest is 3.39 million, so 7.81% of the outstanding shares have been sold short.

Short Interest	3.39M
Short Previous Month	3.14M
Short % of Shares Out	7.81%
Short % of Float	10.66%
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $69.83 million and -$70.96 million in losses. Loss per share was -$5.66.

Revenue	69.83M
Gross Profit	37.66M
Operating Income	-54.44M
Pretax Income	-55.50M
Net Income	-70.96M
EBITDA	-53.27M
EBIT	-54.44M
Loss Per Share	-$5.66

Full Income Statement

Balance Sheet

The company has $231.47 million in cash and $6.97 million in debt, giving a net cash position of $224.50 million or $5.18 per share.

Cash & Cash Equivalents	231.47M
Total Debt	6.97M
Net Cash	224.50M
Net Cash Per Share	$5.18
Equity (Book Value)	313.75M
Book Value Per Share	7.24
Working Capital	245.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$56.10 million and capital expenditures -$3.32 million, giving a free cash flow of -$59.43 million.

Operating Cash Flow	-56.10M
Capital Expenditures	-3.32M
Free Cash Flow	-59.43M
FCF Per Share	-$1.37

Full Cash Flow Statement

Margins

Gross margin is 53.93%, with operating and profit margins of -77.96% and -101.62%.

Gross Margin	53.93%
Operating Margin	-77.96%
Pretax Margin	-101.62%
Profit Margin	-101.62%
EBITDA Margin	-76.29%
EBIT Margin	-77.96%
FCF Margin	n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-150.89%
Shareholder Yield	-150.89%
Earnings Yield	-11.73%
FCF Yield	-9.83%

Analyst Forecast

The average price target for Beta Bionics is $26.67, which is 91.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26.67
Price Target Difference	91.18%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Beta Bionics has an Altman Z-Score of 18.97 and a Piotroski F-Score of 2.

Altman Z-Score	18.97
Piotroski F-Score	2